Oramed Pharmaceuticals (ORMP) Current Deferred Revenue (2015 - 2026)

Oramed Pharmaceuticals has reported Current Deferred Revenue for 11 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (changed N/A YoY), and the FY2025 full-year result was $1.4 million, changed N/A from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $1.5 million, up from $1.4 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $2.0 million in Q1 2022, with the low at $674000.0 in Q1 2023.
• Historically, Current Deferred Revenue has averaged $1.5 million across 4 years, with a median of $1.4 million in 2025.
• The largest YoY upside for Current Deferred Revenue was 66.3% in 2023 against a maximum downside of 66.3% in 2023.
• Oramed Pharmaceuticals' Current Deferred Revenue stood at $1.3 million in 2022, then sank by 49.7% to $674000.0 in 2023, then soared by 100.74% to $1.4 million in 2025, then advanced by 8.72% to $1.5 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $986000.0 (Q3 2025), per Business Quant data.